Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Cirrhosis: new research provides a basis for rational and targeted treatments.

Iredale JP.

BMJ. 2003 Jul 19;327(7407):143-7. Review. No abstract available.

2.

Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review).

Consolo M, Amoroso A, Spandidos DA, Mazzarino MC.

Int J Mol Med. 2009 Aug;24(2):143-52. Review.

PMID:
19578787
3.

Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies.

Hemmann S, Graf J, Roderfeld M, Roeb E.

J Hepatol. 2007 May;46(5):955-75. Epub 2007 Mar 5. Review.

PMID:
17383048
4.

Differential expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in thioacetamide-induced chronic liver injury.

Park SY, Shin HW, Lee KB, Lee MJ, Jang JJ.

J Korean Med Sci. 2010 Apr;25(4):570-6. doi: 10.3346/jkms.2010.25.4.570. Epub 2010 Mar 19.

5.

Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic.

Muddu AK, Guha IN, Elsharkawy AM, Mann DA.

Int J Biochem Cell Biol. 2007;39(4):695-714. Epub 2006 Oct 7. Review.

PMID:
17110155
6.

Time profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagens in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injury.

Prakobwong S, Pinlaor S, Yongvanit P, Sithithaworn P, Pairojkul C, Hiraku Y.

Int J Parasitol. 2009 Jun;39(7):825-35. doi: 10.1016/j.ijpara.2008.12.002. Epub 2009 Jan 3.

PMID:
19168069
7.

Hepatic fibrosis in paediatric liver disease.

Goldschmidt I, Baumann U.

Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):268-70. doi: 10.1016/j.clinre.2012.03.014. Epub 2012 May 18.

PMID:
22609297
8.

[Treatment and prevention of portal hypertension in patients at elderly and senile patients].

Koviazina IO, Shaposhnikova NA.

Eksp Klin Gastroenterol. 2011;(6):79-81. Review. Russian.

PMID:
22168084
9.

Liver fibrosis: from the bench to clinical targets.

Pinzani M, Rombouts K.

Dig Liver Dis. 2004 Apr;36(4):231-42. Review. Erratum in: Dig Liver Dis. 2004 Aug;36(8):562-3.

PMID:
15115333
10.

[Pathology of liver cirrhosis and portal hypertension].

Bläker H, Theuer D, Otto HF.

Radiologe. 2001 Oct;41(10):833-9. Review. German.

PMID:
11715574
11.
12.

[Basic and clinical research of liver cirrhosis].

Wang JY.

Zhonghua Yi Xue Za Zhi. 2005 Apr 20;85(15):1009-10. Chinese. No abstract available.

PMID:
16029538
13.

Hepatic stellate cells and the reversal of fibrosis.

Kisseleva T, Brenner DA.

J Gastroenterol Hepatol. 2006 Oct;21 Suppl 3:S84-7. Review.

PMID:
16958681
14.

Reversibility of hepatic fibrosis: from the first report of collagenase in the liver to the possibility of gene therapy for recovery.

Okazaki I, Watanabe T, Hozawa S, Niioka M, Arai M, Maruyama K.

Keio J Med. 2001 Jun;50(2):58-65. Review.

15.

Fibrosis and cirrhosis reversibility: clinical features and implications.

Pinzani M, Vizzutti F.

Clin Liver Dis. 2008 Nov;12(4):901-13, x. doi: 10.1016/j.cld.2008.07.006. Review.

PMID:
18984473
16.

[Indications for splenectomy in cirrhosis].

Lorriaux A, Gentit F.

Sem Hop. 1970 Sep 10;46(37):2337-40. French. No abstract available.

PMID:
4319022
17.
18.

[Hepatic fibrosis: role of matrix metalloproteases and TGFbeta].

Sentíes-Gómez MD, Gálvez-Gastélum FJ, Meza-García E, Armendáriz-Borunda J.

Gac Med Mex. 2005 Jul-Aug;141(4):315-22. Review. Spanish.

PMID:
16164129
19.

The management of portal hypertension: rational basis, available treatments and future options.

Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG.

J Hepatol. 2008;48 Suppl 1:S68-92. doi: 10.1016/j.jhep.2008.01.021. Epub 2008 Feb 12. Review.

20.

Recent developments in targeting liver fibrosis.

Iredale J.

Clin Med (Lond). 2008 Feb;8(1):29-31. Review. No abstract available.

PMID:
18335665

Supplemental Content

Support Center